Literature DB >> 19411065

Agonizing integrin antagonists?

Sara M Weis1, Dwayne G Stupack, David A Cheresh.   

Abstract

A recent study published in Nature Medicine reports that low-dose treatment with RGD-mimetic integrin inhibitors may paradoxically enhance angiogenesis and tumor growth. This work implies that delivery of these agents should be redesigned in order to avoid nanomolar plasma concentrations and to improve their efficacy to treat human cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411065     DOI: 10.1016/j.ccr.2009.04.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  Integrins as therapeutic targets: lessons and opportunities.

Authors:  Dermot Cox; Marian Brennan; Niamh Moran
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

Review 2.  Transdominant regulation of integrin function: mechanisms of crosstalk.

Authors:  Annette M Gonzalez; Ramona Bhattacharya; Gregory W deHart; Jonathan C R Jones
Journal:  Cell Signal       Date:  2009-10-27       Impact factor: 4.315

3.  Vinculin activators target integrins from within the cell to increase melanoma sensitivity to chemotherapy.

Authors:  Elke S Nelson; Andrew W Folkmann; Michael D Henry; Kris A DeMali
Journal:  Mol Cancer Res       Date:  2011-04-01       Impact factor: 5.852

4.  Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer.

Authors:  Elena Shinderman-Maman; Keren Cohen; Dotan Moskovich; Aleck Hercbergs; Haim Werner; Paul J Davis; Martin Ellis; Osnat Ashur-Fabian
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

5.  Side chain effect in the modulation of αvβ35β1 integrin activity via clickable isoxazoline-RGD-mimetics: development of molecular delivery systems.

Authors:  Lucia Ferrazzano; Monica Baiula; Dario Corbisiero; Eleonora Potenza; Samantha Deianira Dattoli; Santi Spampinato; Laura Belvisi; Monica Civera; Alessandra Tolomelli
Journal:  Sci Rep       Date:  2020-05-04       Impact factor: 4.379

Review 6.  Emerging therapeutic opportunities for integrin inhibitors.

Authors:  R J Slack; S J F Macdonald; J A Roper; R G Jenkins; R J D Hatley
Journal:  Nat Rev Drug Discov       Date:  2021-09-17       Impact factor: 84.694

7.  Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer.

Authors:  Andrew R Reynolds
Journal:  Dose Response       Date:  2010-04-23       Impact factor: 2.658

8.  An in vivo neovascularization assay for screening regulators of angiogenesis and assessing their effects on pre-existing vessels.

Authors:  Witold W Kilarski; Ludvig Petersson; Peder Fredlund Fuchs; Marcin S Zielinski; Pär Gerwins
Journal:  Angiogenesis       Date:  2012-08-24       Impact factor: 9.596

9.  Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via αvβ3 integrin in myeloma cells.

Authors:  Keren Cohen; Nir Flint; Shachar Shalev; Daniel Erez; Tal Baharal; Paul J Davis; Aleck Hercbergs; Martin Ellis; Osnat Ashur-Fabian
Journal:  Oncotarget       Date:  2014-08-15

10.  Progesterone Treatment Attenuates Glycolytic Metabolism and Induces Senescence in Glioblastoma.

Authors:  Fahim Atif; Seema Yousuf; Claudia Espinosa-Garcia; Elena Sergeeva; Donald G Stein
Journal:  Sci Rep       Date:  2019-01-30       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.